CLIP3 Antibody

What is CLIP3 and what cellular functions does it mediate?

CLIP3 belongs to the cytoplasmic linker protein 170 family, containing a cytoskeleton-associated protein glycine-rich domain that facilitates interactions between microtubules and cellular organelles. The protein plays a dual role in cellular function: it mediates T cell apoptosis by facilitating the association of tubulin with lipid raft ganglioside GD3, while also functioning as a scaffold protein that promotes membrane localization of phosphorylated protein kinase B . CLIP3 is predominantly localized to Golgi stacks and tubulovesicular elements juxtaposed to Golgi cisternae, with particularly notable expression in brain, skin, and uterus tissues .

Methodologically, when investigating CLIP3 functions, researchers should consider using complementary approaches such as co-immunoprecipitation to identify interaction partners and subcellular fractionation to confirm its localization pattern. Additionally, siRNA knockdown experiments can validate CLIP3's role in specific cellular processes by observing phenotypic changes following its downregulation.

What are the common applications for CLIP3 antibodies in research?

CLIP3 antibodies are versatile tools applicable across multiple experimental techniques:

When designing experiments, researchers should include both positive controls (tissues with known CLIP3 expression like brain) and negative controls (antibody blocked with immunizing peptide) to ensure specificity . The antibody has demonstrated reactivity with human, mouse, and rat samples, making it suitable for comparative studies across these species.

How should CLIP3 antibodies be stored and handled to maintain optimal activity?

For optimal antibody performance, CLIP3 antibodies should be stored at -20°C, where they maintain stability for approximately one year . The commercial formulation typically includes PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide as preservatives. When working with these antibodies:

• Avoid repeated freeze-thaw cycles, which can lead to protein denaturation and reduced activity

• When removing an aliquot, allow the antibody to warm to room temperature before opening to prevent condensation

• Consider preparing working aliquots to minimize freeze-thaw cycles

• Return the antibody promptly to -20°C after use

• For diluted working solutions, store at 4°C and use within 1-2 weeks

These handling procedures apply to most CLIP3 antibody formulations, including the rabbit polyclonal antibodies that are commonly used in research settings .

How can researchers validate the specificity of CLIP3 antibodies in their experimental system?

Antibody validation is critical for ensuring experimental rigor. For CLIP3 antibodies, a comprehensive validation strategy should include:

• Peptide competition assays: Pre-incubate antibody with the immunizing peptide (derived from human CLIP3 AA range 361-410) before application in Western blot or immunofluorescence to confirm binding specificity

• Genetic controls: Use CLIP3 knockout or knockdown systems to confirm the absence of signal

• Recombinant protein controls: Test antibody against purified recombinant CLIP3 protein

• Cross-reactivity assessment: Test against closely related proteins, particularly other CAP-Gly domain-containing proteins

• Multiple antibody concordance: Compare results using antibodies raised against different epitopes of CLIP3

Researchers should document validation results thoroughly, as antibody performance can vary significantly between experimental contexts. As shown in validation images, properly validated CLIP3 antibodies show specific staining in A549 cells that is completely blocked by immunizing peptide, and a distinct 60kD band in Western blots that disappears when blocked with the synthesized peptide .

What considerations should be made when investigating CLIP3 in the context of T cell apoptosis?

When studying CLIP3's role in T cell apoptosis:

• Cell preparation: Isolate primary T cells or use established T cell lines (e.g., Jurkat)

• Apoptotic stimuli selection: Consider using anti-Fas antibodies, staurosporine, or activation-induced cell death models

• CLIP3-GD3 interaction analysis: Employ co-immunoprecipitation assays followed by Western blotting or mass spectrometry

• Subcellular localization: Track CLIP3 redistribution during apoptosis using time-lapse confocal microscopy

• Functional analysis: Compare apoptotic indices between CLIP3-silenced and control cells

The experimental design should account for CLIP3's specific role in facilitating the association between tubulin and lipid raft ganglioside GD3 . This mechanism is crucial for mitochondrial-mediated apoptotic pathways in T cells. Researchers should include appropriate controls for both the apoptotic process (e.g., caspase inhibitors) and for CLIP3 expression/function.

How can researchers effectively investigate alternative splicing variants of CLIP3?

Alternative splicing creates functionally diverse CLIP3 variants that require specialized approaches for investigation:

• Transcript identification: Design PCR primers spanning exon junctions to selectively amplify specific splice variants

• Quantitative analysis: Employ qRT-PCR with splice variant-specific primers to measure relative expression levels

• Protein isoform detection: Use antibodies targeting splice-specific regions, or combine immunoprecipitation with mass spectrometry

• Functional characterization: Create expression constructs for individual variants for comparative functional studies

• Context-dependent expression: Analyze variant expression across tissues, developmental stages, or disease states

When selecting CLIP3 antibodies for splice variant research, determine which epitope region is recognized (e.g., AA range 361-410) and whether this region is preserved across variants of interest. For comprehensive analysis, researchers may need to employ multiple antibodies targeting different protein regions to capture the full spectrum of CLIP3 variants .

What protocol optimizations are recommended for CLIP3 antibody use in Western blotting?

For optimal Western blot results with CLIP3 antibodies:

The protocol should be validated using positive control tissues known to express CLIP3, such as brain tissue lysates. When analyzing Western blot results, researchers should look for a specific band at approximately 60kD, which corresponds to the expected molecular weight of CLIP3 . Additional bands may represent alternative splice variants or post-translational modifications and should be characterized further if observed consistently.

What are the critical parameters for successful immunofluorescence staining of CLIP3?

For high-quality immunofluorescence detection of CLIP3:

• Fixation method: 4% paraformaldehyde (10-15 minutes) preserves CLIP3 localization while maintaining cellular architecture

• Permeabilization: 0.1-0.2% Triton X-100 (10 minutes) allows antibody access to intracellular CLIP3

• Blocking: 2-5% BSA or normal serum (1 hour) reduces non-specific binding

• Primary antibody: Use at 1:200-1:1000 dilution in blocking buffer, incubate overnight at 4°C

• Secondary antibody: Fluorophore-conjugated anti-rabbit IgG at 1:500-1:1000

• Counterstaining: DAPI for nuclei and phalloidin for actin filaments provide contextual markers

• Mounting: Anti-fade mounting medium extends fluorescence signal stability

When imaging, focus on the perinuclear region where CLIP3 typically localizes within the Golgi apparatus . Co-staining with Golgi markers (GM130, TGN46) can confirm proper localization. For advanced applications, super-resolution microscopy techniques like STED or STORM can resolve CLIP3's association with tubulovesicular elements at the Golgi-endosome interface.

How should researchers approach antigen retrieval for CLIP3 immunohistochemistry?

Effective antigen retrieval is critical for CLIP3 immunohistochemistry in formalin-fixed, paraffin-embedded tissues:

• Preferred method: Heat-induced epitope retrieval using Tris-EDTA buffer (pH 9.0)

• Heating protocol: 95-98°C for 20 minutes in a water bath or pressure cooker

• Cooling period: Allow slides to cool gradually in retrieval solution (15-20 minutes)

• Section thickness: Optimal results with 4-5 μm sections

• Antibody dilution: 1:100-1:300 for overnight incubation at 4°C

• Detection system: Polymer-based detection systems provide superior sensitivity and reduced background

These parameters have been validated for human tonsil tissues, where specific CLIP3 staining patterns can be observed . The alkaline pH (9.0) Tris-EDTA buffer is particularly effective for retrieving CLIP3 epitopes that may be masked during formaldehyde fixation. Negative controls should include omission of primary antibody and, ideally, peptide competition to confirm staining specificity.

How can researchers address inconsistent CLIP3 antibody staining patterns across different cell types?

Inconsistent staining patterns may reflect biological variations in CLIP3 expression or technical issues:

• Cell-type variation: CLIP3 shows tissue-specific expression, with notable presence in brain, skin, and uterus tissues . Differential expression across cell types is expected and should be documented.

• Fixation sensitivity: Different cell types may require optimized fixation protocols:

  • Epithelial cells: Standard 4% PFA for 15 minutes

  • Neuronal cells: Brief fixation (5-10 minutes) or lower PFA concentration (2%)

  • Primary cultures: May require gentler fixation than cell lines

• Subcellular localization shifts: CLIP3 localization can change with:

  • Cell cycle stage: Document cell cycle position when comparing patterns

  • Cellular activation: Signaling events may trigger CLIP3 redistribution

  • Stress conditions: Cellular stress can alter protein localization

• Antibody validation: Confirm antibody specificity in each cell type using:

  • Peptide competition assays

  • siRNA knockdown controls

  • Comparison with mRNA expression data

When interpreting varied staining patterns, consider CLIP3's multiple functions in different cellular compartments. Its role in TGN-endosome dynamics and as a scaffold for AKT kinase family members suggests potential redistribution based on cellular state .

What approaches can resolve contradictory results between different CLIP3 antibody clones?

When faced with contradictory results from different CLIP3 antibody clones:

• Epitope mapping: Identify the specific regions recognized by each antibody. Different antibodies may target regions that are:

  • Differentially accessible in various experimental conditions

  • Affected by post-translational modifications

  • Present only in certain splice variants

  • Involved in protein-protein interactions

• Validation strategy:

  • Test each antibody against recombinant CLIP3 protein

  • Perform peptide competition assays for each antibody

  • Compare reactivity in CLIP3 knockout/knockdown systems

  • Assess reactivity across species if using cross-reactive antibodies

• Multi-method approach: Combine multiple techniques to confirm findings:

  • Complement antibody-based detection with mRNA analysis

  • Use tagged CLIP3 constructs as positive controls

  • Apply proximity ligation assays to validate protein interactions

  • Consider mass spectrometry-based validation for protein identification

• Documentation and reporting: Thoroughly document all antibody information (catalog number, lot, epitope) when reporting results to facilitate reproducibility and comparison across studies .

The field of antibody research has established that approximately 20% of antibodies may show inconsistent results between different clones, making thorough validation essential for reliable research outcomes .

How can single-cell variability in CLIP3 expression be addressed in immunofluorescence studies?

Single-cell variability in CLIP3 expression presents challenges for data interpretation in immunofluorescence studies:

• Quantification approaches:

  • Implement automated image analysis using CellProfiler or similar software

  • Measure integrated density rather than maximum intensity

  • Establish clear thresholding criteria for positive vs. negative cells

  • Report distribution patterns (histograms) rather than simple means

• Biological correlation:

  • Co-stain for cell cycle markers (Ki67, PCNA) to correlate CLIP3 expression with proliferation status

  • Assess correlation with Golgi morphology markers

  • Examine relationship to cell polarity or migration status

  • Consider relationship to metabolic markers if studying CLIP3's role in glucose transport

• Statistical considerations:

  • Increase sample size (analyze >100 cells per condition)

  • Apply appropriate statistical tests for non-normally distributed data

  • Use hierarchical analysis that accounts for both technical and biological replicates

  • Consider dimensionality reduction techniques for multiparameter analyses

• Experimental controls:

  • Include cells with known CLIP3 overexpression or knockdown

  • Use Z-stack acquisitions to ensure complete signal capture

  • Standardize exposure settings across all experimental conditions

  • Include biological controls representing different expression levels

The inherent cell-to-cell variability in CLIP3 expression likely reflects its dynamic roles in cellular processes, including its involvement in TGN-endosome dynamics and potential redistribution during signaling events .

What considerations should be made when designing CLIP3 antibody panels for multi-parameter studies?

Designing effective CLIP3 antibody panels for multi-parameter studies requires careful planning:

• Antibody compatibility assessment:

  • Test for cross-reactivity between antibodies in the panel

  • Ensure secondary antibody specificity when using multiple primaries

  • Validate antibody performance in multiplexed settings

  • Consider using directly conjugated antibodies to avoid species conflicts

• Epitope accessibility in multiplexed protocols:

  • Optimize fixation and permeabilization for all target proteins

  • Test sequential versus simultaneous antibody incubation

  • Consider the order of antibody application if sequential staining is required

  • Test for epitope masking when targets are in close proximity

• Signal separation strategies:

  • Select fluorophores with minimal spectral overlap

  • Include single-color controls for spectral compensation

  • Use spectral unmixing for closely overlapping fluorophores

  • Consider chromogenic multiplex IHC for tissue analysis

• Functional correlation markers:

  • Include markers for Golgi/TGN compartments (GM130, TGN46)

  • Add markers for microtubule cytoskeleton (α-tubulin, EB1)

  • Consider AKT pathway components given CLIP3's scaffold function

  • Include cell type-specific markers when working with heterogeneous populations

Multi-parameter approaches are particularly valuable when investigating CLIP3's dual roles in TGN-endosome dynamics and as a scaffold for signaling proteins like AKT .

How can researchers effectively study the interaction between CLIP3 and the AKT signaling pathway?

To investigate CLIP3's role in AKT signaling:

• Co-localization analysis:

  • Perform dual immunofluorescence for CLIP3 and phospho-AKT

  • Quantify co-localization using Pearson's or Mander's coefficients

  • Use super-resolution microscopy to resolve spatial relationships at the membrane

  • Implement live-cell imaging to track dynamic interactions

• Biochemical interaction studies:

  • Conduct co-immunoprecipitation assays with CLIP3 and AKT antibodies

  • Perform proximity ligation assays to confirm direct interaction

  • Use GST-pulldown assays with purified components to map interaction domains

  • Consider FRET-based approaches to demonstrate direct interaction in living cells

• Functional analysis:

  • Compare AKT phosphorylation status in CLIP3 knockdown/overexpression systems

  • Assess downstream AKT targets like GSK3β and FOXO1

  • Measure glucose uptake in adipocytes as a functional readout of CLIP3-AKT pathway

  • Examine effects of CLIP3 manipulation on insulin signaling

• Structure-function analysis:

  • Create deletion constructs to identify domains required for AKT interaction

  • Perform site-directed mutagenesis of key residues

  • Assess phosphorylation-dependent interactions

  • Generate domain-specific antibodies to monitor conformational changes

This integrated approach leverages CLIP3's established role as a scaffold protein that promotes membrane localization of phosphorylated AKT, thereby influencing glucose transport particularly in adipocytes .

What methodological approaches can distinguish between different pools of CLIP3 in subcellular compartments?

Distinguishing between different subcellular pools of CLIP3 requires specialized approaches:

• Subcellular fractionation techniques:

  • Differential centrifugation to separate major organelles

  • Density gradient separation for finer resolution

  • Immunoisolation of specific compartments using magnetic beads

  • Western blot analysis of fractions using CLIP3 antibody alongside compartment markers

• Advanced microscopy approaches:

  • FRAP (Fluorescence Recovery After Photobleaching) to measure protein mobility

  • Photoactivation of tagged CLIP3 to track movement between compartments

  • Correlative light and electron microscopy for ultrastructural localization

  • Live-cell imaging with compartment-specific markers

• Proximity-based labeling:

  • BioID or APEX2 fusion proteins to identify compartment-specific interaction partners

  • Spatially-restricted enzymatic tagging to label proteins in specific microdomains

  • Compartment-specific crosslinking to capture transient interactions

  • Split-GFP complementation to visualize interactions in specific locations

• Functional manipulation:

  • Use of pharmacological inhibitors of vesicular trafficking

  • Temperature blocks to arrest specific trafficking steps

  • Optogenetic recruitment to specific compartments

  • Creation of chimeric CLIP3 with compartment-specific targeting sequences

These approaches can help dissect CLIP3's distribution between its known localizations at Golgi stacks and tubulovesicular elements, providing insight into its dynamic roles in TGN-endosome trafficking and membrane signaling platforms .